Barclays
AVDL

Barclays’s Avadel Pharmaceuticals AVDL Stock Holding History

Barclays’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-148,858
Closed -$3.21M – 5044
2025
Q4 		$3.21M Sell
148,858
-1,515
-1% -$29.4K ﹤0.01% 2581
2025
Q3 		$2.3M Sell
150,373
-32,485
-18% -$423K ﹤0.01% 2790
2025
Q2 		$1.62M Sell
182,858
-152,067
-45% -$1.34M ﹤0.01% 3016
2025
Q1 		$2.62M Buy
334,925
+164,505
+97% +$1.38M ﹤0.01% 2427
2024
Q4 		$1.79M Sell
170,420
-222,271
-57% -$2.7M ﹤0.01% 2969
2024
Q3 		$5.15M Buy
392,691
+123,430
+46% +$1.88M ﹤0.01% 2074
2024
Q2 		$3.79M Buy
+269,261
New +$4.39M ﹤0.01% 1707
2024
Q1 		– Sell
-24
Closed -$339 – 5069
2023
Q4 		$339 Sell
24
-24
-50% -$282 ﹤0.01% 5143
2023
Q3 		$494 Sell
48
-49,287
-100% -$660K ﹤0.01% 4511
2023
Q2 		$813K Buy
+49,335
New +$641K ﹤0.01% 2445
2021
Q4 		– Sell
-154
Closed -$1K – 4126
2021
Q3 		$1K Sell
154
-554
-78% -$4.36K ﹤0.01% 4688
2021
Q2 		$4K Sell
708
-13,595
-95% -$108K ﹤0.01% 4753
2021
Q1 		$130K Buy
14,303
+88
+0.6% +$711 ﹤0.01% 3892
2020
Q4 		$95K Buy
14,215
+200
+1% +$1.25K ﹤0.01% 4150
2020
Q3 		$71K Sell
14,015
-26,600
-65% -$194K ﹤0.01% 4422
2020
Q2 		$328K Buy
40,615
+26,566
+189% +$234K ﹤0.01% 3667
2020
Q1 		$111K Buy
+14,049
New +$108K ﹤0.01% 4726
2019
Q2 		– Sell
-7
Closed – – 6929
2019
Q1 		$0 Sell
7
-69
-91% -$156 ﹤0.01% 6996
2018
Q4 		$0 Sell
76
-145
-66% -$493 ﹤0.01% 6922
2018
Q3 		$1K Sell
221
-800
-78% -$4.32K ﹤0.01% 7000
2018
Q2 		$6K Sell
1,021
-1,150
-53% -$8.07K ﹤0.01% 6663
2018
Q1 		$15K Sell
2,171
-5,399
-71% -$47.5K ﹤0.01% 6522
2017
Q4 		$61K Buy
7,570
+3,505
+86% +$32.9K ﹤0.01% 5624
2017
Q3 		$43K Buy
4,065
+1,000
+33% +$9.55K ﹤0.01% 5427
2017
Q2 		$34K Buy
3,065
+3,000
+4,615% +$30.1K ﹤0.01% 5539
2017
Q1 		$0 Sell
65
-1,320
-95% -$13.2K ﹤0.01% 6740
2016
Q4 		$14K Sell
1,385
-142
-9% -$1.56K ﹤0.01% 5764
2016
Q3 		$19K Buy
1,527
+938
+159% +$12.3K ﹤0.01% 5488
2016
Q2 		$6K Sell
589
-7,381
-93% -$78.7K ﹤0.01% 5689
2016
Q1 		$88K Buy
7,970
+7,027
+745% +$69.8K ﹤0.01% 4429
2015
Q4 		$12K Sell
943
-9,868
-91% -$154K ﹤0.01% 5337
2015
Q3 		$173K Sell
10,811
-13,644
-56% -$301K ﹤0.01% 4235
2015
Q2 		$513K Buy
24,455
+17,105
+233% +$307K ﹤0.01% 3457
2015
Q1 		$124K Buy
7,350
+1,347
+22% +$21.1K ﹤0.01% 4702
2014
Q4 		$102K Buy
6,003
+5,734
+2,132% +$81.9K ﹤0.01% 5190
2014
Q3 		$4K Hold
269
– – ﹤0.01% 7228
2014
Q2 		$4K Buy
269
+1
+0.4% +$12 ﹤0.01% 7171
2014
Q1 		$3K Sell
268
-1,850
-87% -$19.8K ﹤0.01% 7320
2013
Q4 		$17K Sell
2,118
-1,009
-32% -$7.12K ﹤0.01% 6791
2013
Q3 		$19K Hold
3,127
– – ﹤0.01% 6544
2013
Q2 		$19K Buy
+3,127
New +$16.1K ﹤0.01% 6852

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Barclays's AVDL Position: Q1 2026 in Review

Barclays sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 148,858 shares — an estimated $3.21M sold.

Barclays first reported a position in AVDL in Q2 2013 and held it in 41 quarters. The position peaked at $5.15M in Q3 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Barclays reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 148,858 Avadel Pharmaceuticals shares in Q1 2026, an estimated $3.21M.
  • Barclays first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 41 quarters.
  • Barclays's Avadel Pharmaceuticals position peaked at $5.15M in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.